Dana Pizzuti - 03 Jan 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Med and Dev Officer
Signature
Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
03 Jan 2025
Net transactions value
-$478,900
Form type
4
Filing time
07 Jan 2025, 16:30:08 UTC
Previous filing
07 Oct 2024
Next filing
05 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $253,350 +15,000 +51% $16.89 44,248 03 Jan 2025 Direct
transaction CRNX Common Stock Sale $781,350 -15,000 -34% $52.09 29,248 03 Jan 2025 Direct F1, F2, F3
transaction CRNX Common Stock Options Exercise $49,100 +2,500 +8.5% $19.64 31,748 07 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock option (Right to Buy) Options Exercise $0 -15,000 -11% $0.000000 124,042 03 Jan 2025 Common Stock 15,000 $16.89 Direct F4
transaction CRNX Stock Option (Right to Buy) Options Exercise $0 -2,500 -12% $0.000000 18,500 07 Jan 2025 Common Stock 2,500 $19.64 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $52.09 per share. The range of sales prices on the transaction date was $51.60 to $52.60 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F3 Includes 741 shares acquired under the Issuer's Employee Stock Purchase Plan.
F4 The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
F5 1/48th of the shares subject to the option vested on April 1, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.